GB2075341A

GB2075341A - Pharmaceutical compositions

Info

Publication number: GB2075341A
Application number: GB8112381A
Authority: GB
Original assignee: Smith and Nephew Associated Companies PLC
Current assignee: Smith and Nephew PLC
Priority date: 1980-04-18
Filing date: 1981-04-21
Publication date: 1981-11-18
Also published as: EP0038698B1; US4421741A; JPS56166114A; CA1171790A; IE51085B1; ZA812262B; EP0038698A3; AU6947781A; EP0038698A2; NZ196700A; ATE15596T1; IE810785L; DE3172298D1; US4349563A; GB2075341B

Abstract

An anti-inflammatory phamaceutical composition is described which is adapted for topical application to the eye and contains as active principle a compound of formulaor a pharmaceutically acceptable salt thereof where R1 is a chlorine atom or a methyl group, R2 is a hydrogen atom or a methyl group and R3 is a hydrogen atom or a methyl group. The composition may be used to treat ocular inflammation.

Description

1

GB 2 075 341 A

1

SPECIFICATION Pharmaceutical compositions

5 The present invention relates to a pharmaceutical composition, its preparation and use. More specifically this invention relates to an anti-inflammatory s ophthalmic composition comprising as active principle an arylacetic acid or a pharmaceutical^ accept-10 able salt thereof and to the preparation and use of < such compositions.

Steroidal anti-inflammatory agents are well known which are effective in controlling inflammation in the eye. However the use of steroids may give rise to 15 undesirable side-effects such as the masking or enhancement of corneal infections or cause elevation of intraocular pressure, so that for certain ophthalmic compositions some authorities would prefer to employ a non-steroidal anti-inflammatory agent. 20 Whilst a large number of non-steroidal antiinflammatory agents including arylacetic acids and their salts are known to be effective in the treatment of inflammatory conditions such as arthritis when administered systematically it has been found that 25 such agents in general have little or no effectiveness when applied topically to the eye, for example, in the form of eyedrops. In our experience there is no correlation between known systemic ani-inflammatory activity and anti-inflammatory effectiveness in the 30 eye. It has therefore been impossible to predict whether a given non-steroidal anti-inflammatory agent would be effective in the eye or not. In fact so far no arylacetic acid has found clinical use fortopi-cal administration in the eye.

35 Clearly it is desirable to provide a composition which may be administered to the eye to reduce inflammation and which does not depend for its effectiveness on the presence of a steroid.

A class of non-steroidal anti-inflammatory arylace-40 tic acids is disclosed in US Patent No. 375 2826 (see also British Patent No. 1195628). Whilst the pharmaceutical use of the 5-benzoyl pyrrole alkanoic acids in the systemic treatment of rheumatoid arthritis and analgesia was described, no suggestion of 45 the desirability of ophthalmic application was made.

The present invention provides an antiinflammatory ophthalmix composition comprising as active principle a compound of formula (I):

CHR;

COOH

CH3

or a pharmaceutical acceptable salt thereof wherein R, is a chlorine atom or a methyl group, R2 is 60 a hydrogen atom or a methyl group and R3 is a hydrogen atom or a methyl group. This adaption of such compositions for topical administration to the eye is surprising.

The compounds of the formula (I) are described in 65 US Patent No. 3752826 (McNeil) and are now known to be excellent pharmaceutical agents.

A preferred compound of the formula (I) is 5 - (p -methylbenzoyl) -1 - methylpyrrole - 2 - acetic acid (where R, is methyl and R2 and R3 are both hydrogen) hereinafter known as "tolmetin".

Most suitably the compound of the formula (I) is in the form of a salt suitable for ocular administration.

The composition of this invention is preferably presented as a clear, sterile aqueous solution with the active principle present as a water-soluble salt. Particularly apt salts include the sodium or potassium salt of which the sodium salt is preferred.

From the foregoing it will be realised that highly favoured active principles for use in the compositions of this invention are the sodium and potassium salts of tolmetin and that the preferred principle is the sodium salt of tolmetin.

Most suitably the composition of this invention will contain from 0.1-10% of the active principle as hereinbefore described, more favourably from 0.4-7% of said active principle and preferably 0.5-5%, forexample 1-2%or2-5%ofsaid active principle, (% terms when used herein are expressed on a wt/wt basis). Surprisingly clear aqueous solutions containing such levels of the active principle can be prepared and are stable to sterilisation techniques so that it is possible to provide the compositions of this invention in sterile form which is of great desirability.

In general compositions containing low levels of the active principle will require the presence of tonicity adjusting agents to bring the tonicity of the solution within the presecribed ranges. Most suitably the composition of this invention is rendered substantially isotonic, that is to say in terms of sodium chloride equivalent from 0.4 to 1.8% and more suitably from 0.6 to 1.5%. An isotonic solution has a sodium chloride equivalent of 0.9%. Adiscussion of isotonicity, sodium chloride equivalent and a list of tonicity agents is given in Remingtons' Pharmaceutical Sciences, Fifteenth Edition, p. 1405-1412.

Aptly the compositions of this invention will contain an antioxidant. Suitable antioxidants for use in this invention include citrate salts, N-acetyl cysteine, sodium thiosulphate, sodium metabisulphate and thiourea. A preferred antioxidant is trisodium citrate.

Suitably the antioxidant is present in an amount from 0.01 to 2.5%, preferably 0.05 to 2% and more preferably is 0.5 to 1.5% for example 1%.

Aptly the compositions of this invention will contain a metal ion sequestering agent. Suitable metal ion sequestering agents for use in this invention include sodium citrate, 8-hydroxyquinoline and its salts and ethylenediamine tetraacetic acid and its salts for example the disodium salt. A preferred metal ion sequestering agent is trisodium citrate.

Suitably the sequestering agent is present in an amount from 0.001 to 2% and more preferably is from 0.5 to 1.5%.

From the aforementioned it is clear that an antioxidant and metal ion sequestering agent may be used in combination. A preferred agent which possesses both properties is trisodium citrate. The presence of forexample sodium citrate has been found to reduce the tendency of the compositions to dis70

75

80

85

90

95

100

105

110

115

120

125

130

2

GB 2 075 341 A

2

colour on storage by oxidation which may be catalysed by metal ions such as those of group lla, lb, lib and IVbofthe periodic table and in particular copper, ferrous and ferric ions. Secondly the presence of for 5 example trisdium citrate as a sequestering agent has been found to prevent the precipitation of insoluble tolmetin salts of the metal ions described above and in particular with calcium ions which may leach from a glass bottle.

10 Optionally compositions of this invention may be buffered to a pH value of from 6.0 to 8.6. For solution at the higher value of pH for example 8.5 the preferred buffering system is a mixture of sodium borate and boric acid. At the preferred values of 7.0 to 8.0 15 the preferred buffering agents are a mixture of the alkali metal salts of orthophosphoric acid. However the addition of a buffering system to the composition may introduce inadvertently deleterious metal ions as described above and thereby require more 20 chelating agent present.

Compositions of the present invention may be prepared advantageously without the presence of a bufferto have a pH value of 6.0 to 8.6 and more preferably from 7.0 to 8.0 for example 7.5. 25 Optionally the compositions of this invention will contain a stabilizer such as a surface active agent for example poiyoxyethylene sorbitan fatty acid esters (commonly called polysorbate and often called Tween) or polyoxypropyiene - poiyoxyethylene diol 30 block copolymers (commonly called Poloxamer). A preferred stabiliser is poiyoxyethylene sorbitan monooleate, Tween 80. The presence of a stabiliser is not preferred.

Normally the compositions of the invention will 35 contain a preservative such as a phenylmercuric salt of nitric, boric or acetic acid or a quaternary ammonium compound such as benzalkonium chloride or chlorbutanol orthiomersal, the sodium salt of O-carboxyphenyl thioethyl mercury or 40 phenylethanol or phenoxyethanol, including combinations of thiomersal with phenylethanol or benzalkonium chloride and combinations of phenylmercuric nitrate with phenylethanol or phenoxyethanol.

Preferred preservatives include a combination of 45 thiomersal with phenylethanol and thiomersal with phenoxyethanol. A particularly preferred preservative is a combination of from 0.1 to 1%

phenylethanol with 0.001 to 0.025% thiomersal, a most preferred combination is 0.5% phenylethanol 50 and 0.01%thiomersal.

The particularly favoured form of the composition of the present invention comprises from 0.5 to 5.0% of the sodium salt of tolmetin, from 0.05 to 2% of trisodium citrate, 0.1 to 1 % phenylethanol, 0.001 to 55 0.025% thiomersal in aqueous solution at a pH value of 7.0 to 8.0.

The preferred form of the composition of the present invention comprises from 1 to 2% of the sodium saltoftolmetin, 1%of trisodium citrate, 0.5% 60 phenylethanol, 0.01 % thiomersal in aqueous solution at a pH of 7.5.

In a further particularly favoured form of the composition of the present invention an aminoglycoside or salt thereof may be present as an antibacterial. 65 Aminoglycosides which may be used include neomycin, gentamysin, framycetin, polymixin B, Tobramycin, kanamycin, vancomycin, amikacin and their salts include sulphate and phosphate. Suitably the aminoglycoside or rts salt is present in an 70 amount from 0.1 to 3.0%, more favourably from 0.2 to 1 % and preferably 0.5%.

In a preferred form of the composition of the present invention the antibacterial agent is neomycin or one of its salts, particularly aptly neomycin sulphate. 75 However, in aqueous solution in the absence of a solubilising agent at a pH value of below 8.5 and, more rapidly at a pH value of below 8 the neomycin cation has been found to form with the tolmetin anion an insoluble product. To preventthe insoluble 80 product being precipitated from solution, a solubilising agent is preferably added. This agent contains for example an anion selected from phosphate, citrate, glycerophosphate, sulphate, tartrate or borate.

85 The orthophosphate anion is particularly effective in solubilising neomycin when present in the form of disodium hydrogen orthophosphate or dipotassium hydrogen orthophosphate. Such salts as phosphate may be produced in situ by the addition of suitable 90 amounts of sodium or potassium phosphate and phosphoric acid. However it is preferred that citrate salts are used to aid in the solubilisation of neomycin. The most preferred citrate salt being trisodium citrate. The amount of solubilising anion used 95 depends upon the weight of neomycin present. In general a weight ratio of solubilising anion to neomycin sulphate of 1:1 to 8:1, preferably 2:1 to 3:1 is used.

Alternatively, polyvinyl pyrrolidone may be used 100 of the solubilising anion to maintain the active principles in solution. The amount of polyvinyl pyrrolidone present may be from 1 to 20%, particularly from 5 to 15%.

A further particularly favoured form of the com-105 position of the present invention comprises from 0.4 to 7% of the sodium salt of tolmetin, from 0.2 to 1% of neomycin sulphate, 0.05 to 2% trisodium citrate, 0.1 to 1% phenylethanol, 0.001 to 0.025% thiomersal in an aqueous solution at a pH value of 7.0 to 8.0. 110 The preferred form of the composition of the present invention comprises 2 to 5% of the sodium salt of tolmetin, 0.5% neomycin sulphate, 1 to 2% trisodium citrate, 0.5% phenyl ethanol. 0.01% thiomersal in an aqueous solution at a pH value of 7.5.

115 A further preferred form of the composition of the present invention comprises 2 to 5% of the sodium salt oftolmetin, 0.5% of neomycin sulphate, 10% polyvinyl pyrrolidone, 0.5% phenylethanol, 0.01% thiomersal in an aqueous solution at a pH value of 120 7.5.

Afurther favourable composition of the present invention will contain as preferred antibacterial chloramphenicol in an amount from 0.1 to 3%. Compositions containing chtoroamphenical will normally 125 also contain a solubilising agent for chloroam-phenicol. Solubilising agents for chloramphenicol include sodium borate, polyvinyl alcohol and polyvinyl pyrrolidone. A preferred solubilising agent is polyvinyl pyrrolidone having a number average 130 molecularweight of 40,000. This polyvinyl pyr-

3

GB 2 075 341 A

3

rolidone is known as Plasdone C-30 (Registered trade mark ofGAF Corp.). The amount of polyvinyl pyrrolidone present may be from 1 to 20%, particularly from 5 to 15%.

5 A further particularly favoured form of the composition of the invention contains from 4.0 to 7% of the sodium salt oftolmetin, from 0.1 to 3.0% * chloramphenicol, 5 to 15% polyvinyl pyrrolidone, 0.05 to 2% trisodium citrate, 0.1 to 1.0% 10 phenylethanol, 0.0025 to 0.025%thiomersal in an aqueous solution having a pH value of 7.5.

A further preferred form of the composition of the invention contains from 2 to 5% of the sodium salt of tolmetin, 0.5% chloroamphenicol, 10% polyvinyl 15 pyrrolidone, 0.5 to 1.5% trisodium citrate, 0.5% phenylethanol, 0.01% thiomersal in an aqueous solution having a pH of 7.5.

Generally the compositions of the present invention will be formulated for either a single or multi-20 dose pack. In single dosage form a suitable dose of the composition may be contained in a single cpasule equipped to deliver drops of solution. In this presentation each capsule will hold from 0.3 to 0.7 ml. and will have been sterilised e.g. by autoclaving. 25 More usually the composition will be provided as a multi-dose pack such as neutral glass eye drop bottle with a polypropylene screw cap containing from 5 to 15 ml., usually 6 to 10 ml., for example 7.5 ml. In manufacture sterile bottles or capsules may be filled 30 aseptically with a solution sterilised by filtration. Alternatively the bottle or capsule may be filled, sealed and the bottle or capsule and its contents sterilised by heat, for example by autoclaving.

The concentration of the active ingredient in the 35 composition is so adjusted that each drop delivers a suitable dose for example 0.2 to 5mg. of for example the sodium salt of tolmetin. Generally a drop will contain from 20 to 50 microlitres of solution. The indications for use include pre- and post-operative 40 inflammations, uveitis and conjunctivitis. Administration of the drops will range from hourly to 3 times a day. At each application usually 1 to 2 drops will be given.

In a preferred embodiment the invention provides 45 a clear sterile aqueous solution comprising the sodium salt of tolmetin and neomycin sulphate or chloroamphenicol, a solubiliser, an antioxidant, a sequestering agent and a preservative combination in a multi-dose container provided with a dropper 50 adapted to provide 0.2 to 5mg., more usually 1 to 2mg, of sodium salt oftolmetin in 1 to 5 drops of 20 to 50 microlitres and preferably in 1 to 2 drops of solution.

The invention also embraces a single sterile drop 55 of the said composition in liquid form comprising from 1 to 2mg of the sodium salt of tolmetin.

Such a dosage is clearly distinguished from a dosage formulated for systemic use, which may typically comprise from 100 to 200mg of the sodium salt 60 oftolmetin and is not in sterile form.

In further preferred compositions of the present invention the active principle is contained in an emulsion. Preferred emulsions are those which are of the water-in-oil type, whereby the oil is the con-65 tinuous phase and the aqueous phase is dispersed in it.

Suitably the emulsion will contain from 1 to 10% of the active principle, more suitably 0.5 to 5% and preferably from 2 to 5%. The active principle is suitably 70 tolmetin orthe sodium salt oftolmetin. Preferably the active principle is the sodium salt of tolmetin.

Suitably the emulsion will contain a sequestering agent or antioxidant as hereinbefore described. Particularly suitable sequestering agents or antioxid-75 ants are the salts of citric acid. Preferably the sequestering agent or antioxidant is trisodium citrate. Suitably the sequestering agent or antioxidant is present in an amount from 0.01 to 2.0%, more suitably 0.075 to 1.5% and preferably from 0.1 to 0.5%. 80 Normally any pharmacologically acceptable oil may be used in the emulsions of the present invention. Suitably these oils include vegetable and mineral oils such as castor oil, liquid paraffin, white soft paraffin including mixtures thereof. Suitably the oil 85 phase will contain a mixture of liquid paraffin and white soft paraffin and preferably will contain a mixture of liquid paraffin, white soft paraffin and castor oil. Suitably the oil phase is present in an amount from 40 to 65% and preferably from 45 to 60%. 90 Conventionally the emulsion of the present invention will contain one or more emulsifying agents. Suitable emulsifying agents include clyceryl mono-isostearate, ceto stearyl alcohol, hydrogenated castor oil and sorbitan sesquioleate and including mix-95 tures thereof. Preferred emulsifying agents are glyceryl monoisostearate and glyceryl monoisos-tearate together with sorbitan sesquioleate and hydrogenated castor oil. Suitably the emulsifying agent is present in an amount from 1 to 20%, more suitably 100 from 2.5 to 10%.

Suitably the emulsions of the present invention will contain a preservative. Suitable preservatives include chlorbutanol, chlorocresol, benzalkonium chloride, thiomersal, phenylethanol, phenox-105 yethanol and mixtures thereof. A particularly preferred preservative is phenylethanol. Suitably the preservative is present in an amount from 0.1 to 1% and preferably is 0.5%.

Asuitableform of the emulsion of this invention 110 contains 0.5 to 5% of the sodium salt tolmetin, 0.1 to 0.5% of trisodium citrate, 0.5% phenylethanol, 5.0% glyceryl monoisostearate, 27.5% of liquid paraffin, 20.0% of white soft paraffin, 10.0% of hydrogenated castor oil and 34.9% of water.

115 A preferred form of the emulsion of this invention contains 2 to 5% of the sodium salt oftolmetin, 0.1 to 0.5% of trisodium citrate, 0.5% of phenylethanol, 3.0% of glyceryl monoisostearate, 26.5% of liquid paraffin, 20.0% of white soft paraffin, 10% of hyd-120 rogenated castor oil, 3% of sorbitan sesquioleate and 34.9% water.

A further preferred form of the composition is as a sterile ophthalmic ointment. Suitably the active principle is present as a compound of formula (I) or a 125 pharmaceutically acceptable salt. Particularly suitable compounds are tolmetin orthe sodium salt of tolmetin in either their anhydrous or hydrated forms. Particularly preferred is the anhydrous form of the sodium salt oftolmetin. When in this form the com-130 pound may be sterilised by gamma irradiation with

4

GB 2 075 341 A

4

out discolouration. Suitably the active principle is present in an amount from 0.1 to 10% and preferably from 0.5 to 6%.

Ointment bases suitable for this invention include 45 5 a mixture of white oryellow soft paraffin and liquid paraffin orthe Eye Ointment Basis, comprising wool fat (1 part), liquid paraffin (1 part) and yellow soft paraffin (8 parts), described in the Pharmaceutical Codex 1979 11th Edition p 349. Preferred ointment 50 10 bases include a mixture of white soft paraffin and liquid paraffin in a ratio of 1:0.80to 1:1.

ft is desirable that ophthalmic ointments are sterile, substantially free from foreign particulate contamination and the particle size of the active 55

15 ingredient is reduced to impalpability. It is preferred to prepare and pack the ointment under aseptic conditions by bringing together pre-sterilised ingredients under sterile conditions. The ointment base may be sterilised by melting togetherthe ingredients 60 20 and filtering through an 0.22 micron filter. The sodium salt of tometin may be sterilised by dissolving the salt in water, filtering through a 0.22 micron filter and freeze-drying the sterile solution. The material may then be ground and micronised asepti- 65 25 cally. It is preferred, however, to micronise the anhydrous sodium salt oftolmetin and then sterilise this solid by gamma irradiation at 2.5 Mrad.

For use in ointments of this invention it is preferred thatthe solid sodium salt oftolmetin is micron- 70 30 ised that is to say 99% of the particles are smaller than 20 microns in diameter, 90% of the particles are below 10 microns. The majority of particles are in the range of 1 to 5 microns in diameter.

A short discussion on the desirable properties and 75 35 preparation of sterile ophthalmic ointments is given in Remington's Pharmaceutical Sciences, Fifteenth Edition p. 1503-4.

The particular favoured form of the composition of the present invention comprises a sterile ointment 80 40 containing from 0.5 to 6% of the anhydrous sodium salt oftolmetin and a mixture of white soft paraffin/liquid paraffin in a ratio from 1:0.8to 1:1.

The preferred form of the composition of this invention comprises from 1 to 2% of the anhydrous sodium salt oftolmetin, 52.5% white soft paraffin and from 44.5 to 45.5% liquid paraffin.

In a further form of the present invention the ointment described hereinbefore may suitably contain an antibacterial agent such as an aminoglycoside.or salt thereof or chloramphenical in an amount from 0.1 to 3%.

A particularly favoured form of the composition of the present invention comprises 1 to 2% of the anhydrous sodium salt of tolmetin, 0.5% neomycin sulphate, 52.25% white soft paraffin and from 45.25% to 46.25% liquid paraffin.

Alternatively a second favoured form of the composition comprses 1 to 2% of the anhydrous sodium salt oftolmetin, 1.0% of chloramphenicol, 52.5% white soft paraffin and 44.5 to 45.5% liquid paraffin.

The present invention also envisages a method of treatment of the human or domestic mammal eye which comprises delivering thereto an antiinflammatory composition of this invention.

In order ot demonstrate the effectiveness of the anti-inflammatory compositions of the present invention, tests were carried out by the method given in "A detailed assessment procedure of antiinflammatory effects of drugs on experimental immunogenic uveitis in rabbits". J. J. Ashford, J. W. Lamble in Investigative Ophthalmology 197413 (6) 414-421.

The effect of 1,2 and 5% solutions of the sodium salt oftolmetin compared to vehicle treated eyes in rabbits with unilateral immune uveitis was measured using bolometry.

The rabbits were dosed with 50 microlitres of the drug or vehicle applied topically to the lower conjunctival sac at zero, 2,3,6,8 and 24 hours from the challenge. Representative measurements of corneal temperature were taken at 6,24,48 and 72 hours from the challenge.

% sodium salt

6

24

48

72

oftolmetin hours hours hours hours

1%

-46

-60

+8

+30

2%

-56

-68

-50

+ 15

5%

-60

-83

-78

-60

The table shows the mean percent reduction of a number of sodium salt oftolmetin solutions treated 85 versus vehicle treated groups of the mean corneal temperature for various concentrations of sodium salt oftolmetin.

A study on the anti-inflammatory activity of the sodium salt oftolmetin versus a saline control was 90 carried out in patients subsequent to cataract extraction. Eight patients received 50 microlitres of a 5% aqueous solution of the sodium salt oftolmetin four times daily for a period of 36 days or until the remaining inflammatory changes were minimal. 95 Seven patients received a similar amount of saline four times a day. Each patient also received 1% atropine topically once daily. Atropine causes pupil dilation thereby facilitating fundus examination and reduces the risk of fibrous strands adhering the iris 100 to lens.

By scoring signs and symptoms of inflammation, a noticeable improvement in these patients receiving the sodium salt oftolmetin was seen at day +8 post-operation, a definite improvement was seen at 105 day +15 and by day +22 the difference in the two groups was statistically highly significant.

Example 1

Sodium salt of tolmetin formulations A formulation was prepared containing,

110

Tolmetin sodium dihydrate 2.0 g

T risodium citrate 1.0 g

Boric acid 0.1 g

Phenylmercuric nitrate 0.002 g

5

GB 2 075 341 A

5

Sodium borate, 5% solution to adjust pH to 8.5 Distilled waterto make volume up to 100ml.

The solution was prepared by dissolving phenyl-5 mercuric nitrate in approximately 25ml. of distilled water at room temperature with stirring. Trisodium citrate and boric acid were added and the solution .stirred until both had completely dissolved. Then the sodium salt oftolmetin was dissolved in this sol-10 ution. The pH of the solution was raised to 8.5 by addition of a 5% solution of sodium borate and the 'volume of the solution finally made up to 100ml.

with distilled water.

This solution was sterilised by filtration through a 15 0.22 micron filter from Millipore and packed in multi-dose sterile glass eye-dropper bottles.

Alternatively the solution may be placed in multi-dose glass eye-dropper bottles and the bottles and solution sterilised by autoclaving at 116°C for 30 20 minutes.

Example 2

Sodium salt oftolmetin formulation

A formulation was prepared containing:

25 Tolmetin sodium dihydrate 2.0g

Trisodium citrate 1.0g

Boric acid 0.1 g

Sodium borate 5% solution to adjust pH to 8.5 Distilled waterto make up volume to 100ml. 30 Phenylmercuric nitrate 0.002g

Trisodium citrate, boric acid and the sodium salt of tolmetin were sequentially dissolved in 40ml. of distilled water, the pH of the solution was adjusted to 35 8.5 with a 5% solution of sodium borate and the volume of the solution was made up to 100ml. with distilled water. 10g. of a chelating resin, Chelex 100 Resin (of BioRad Laboratories, Richmond, California) was added to this solution and the mixture stirred 40 together for 30 minutes and the resin was then filtered off.

The phenylmercuric nitrate was dissolved in the filtrate. The pH and volume of the filtrate were readjusted to 8.5 and 100ml.

45 The solution was then filled into the multi-dose eye-dropper bottles in a nitrogen atmosphere and sterilised by autoclaving at116°Cfor30 minutes.

Example 3 50 Sodium salt oftolmetin formulation

A formulation was prepared containing:

"Tolmetin sodium dihydrate 2.0g

T risodium Citrate 1.0g

55 Boric Acid 0.1g

Sodium borate 5% solution to adjust pH to 8.5 Distilled waterto make volume up to 100ml.

The solution was prepared as in Examples 1 and 2. 60 The solution was then filled into unit-dose packs and sterilised by autoclaving at 116°C for 30 minutes. Example 4

Sodium salt oftolmetin — Chloramphenicol formulation

65 A formulation was prepared containing:

Tolmetin sodium dihydrate 5.0g

Chloramphenical 0.5g

Trisodium citrate 1.5g

Boric acid 1.0g

Sodium borate 0.2g Polyvinyl alcohol,

(GOHSENOLGH-17) 3.5g

Phenylmercuric nitrate 0.002g

Sodium hydroxide solution to adjust pH to 7.4 Distilled waterto adjust volume to 100ml.

The solution was prepared by dissolving phenylmercuric nitrate in 40ml. of distilled water with stirring. Then the trisodium citrate, boric acid, sodium borate, polyvinyl alcohol and chloramphenicol were added and dissolved in solution. When all the aforementioned ingredients had completely dissolved, the sodium salt oftolmetin was added to the solution and dissolved with stirring. The pH of the resultant solution was then adjusted to a pH of 7.4 with sodium hydroxide solution and the volume made up to 100ml. with distilled water.

The resultant solution was sterilised by filtration through a 0.22 micron filter and filled into sterile eye-dropper glass bottles.

Example 5

Sodium salt oftolmetin — Chloroamphenicol formulation

A formulation was prepared containing:

Tolmetin sodium dihydrate 1.0g

Chloramphenicol 0.5g

Sodium borate 0.3g

Boric acid 1.0g

Poiyoxyethylene sorbitan monooleate 0.1 g

Phenylmercuric nitrate 0.002g

Benzalkonium chloride 0.001 g

The solution was prepared, sterilised and packaged in the manner of Example 4.

Example 6

Sodium salt oftolmetin — Neomycin sulphate formulation

A formulation was prepared containing:

Tolmetin sodium dihydrate 5.0g

Trisodium citrate 2.0g

Neomycin sulphate 0.5g

Polyvinylpyrrolidone 10.0g

Phenylmercuric nitrate 0.002g

Sodium hydroxide solution to adjust pH to 7.4 Distilled waterto make volume up to 100ml.

The solution was prepared by dissolving the trisodium citrate and phenylmercuric nitrate in 50ml, of distilled water at room temperature. The neomycin sulphate was added and dissolved in this solution. Polyvinyl pyrrolidone was added and the solution stirred to ensure all the ingredients has dissolved. The sodium salt oftolmetin was added and taken up into the solution.

The resultant solution was adjusted to a pH of 7.4 Afith sodium hydroxide and the volume of the solu-

70

75

80

85

90

95

100

105

110

115

120

125

130

6

GB 2 075 341 A

6

tionthe made up to 100ml. with distilled water.

This solution was then sterilised and packaged in the manner of Example 4.

Example 7

5 Sodium salt oftolmetin Ointment formulation A formulation was prepared containing:

Sodium tolmetin dihydrate White soft paraffin 10 Liquid paraffin

5.0g 52.25g 42.75g

The white soft paraffin and liquid paraffin were melted and mixed together to form a homogeneous fluid. This fluid was sterilised whilst hot by passing 15 through a 0.22 micron filter and collected in a sterile mixing vessel.

The sodium salt oftolmetin was dissolved in 40ml. of distilled water and filtered through a 0.22 micron filter. The filtrate was freeze dried under sterile con-20 ditions to give a sterile powder solid which has a particle size of less than 75 microns separated by sieving. The requisite amount of this fine powder was intimately mixed with the white soft paraffin/liquid paraffin mixture to give a sterile ophthal-25 mically acceptable ointment containing the sodium salt oftolmetin.

The ointment was then packed in conventional ointment tubes under sterile conditions.

Example 8 30 Sodium salt of tolmetin formulation

Aformulation was prepared containing:

Tolmetin sodium dihydrate 2.0g

Dipotassium hydrogen phosphate 0.6g

35 Potassium dihydrogen phosphate 0.116g

Polyvinyl alcohol (Gohsenol GL-05) 3.0g

Phenylmercuric nitrate 0.002g

Distilled waterto adjust the volume to 100ml.

40 This solution was then sterilised and packaged in the manner of Example 4.

Example 9

Sodium salt oftolmetin—neomycin formulation Aformulation was prepared containing:

45

Tolmetin sodium dihydrate Neomycin sulphate Disodium hydrogen phosphate Polyvinyl pyrrolidone 50 Thiomersal

5.0g 0.5g I.Og 10.0g 0.02g

Sodium hydroxide solution to adjust the pH to 7.4 Distilled waterto adjust the volume to 100 ml.

70

75

80

85

90

95

This solution was then sterilised and packaged in the manner of Example 4.

Example 11

Sodium salt oftolmetin ointment formulation

Tolmetin sodium anhydrous (micronised) 1.77% White soft paraffin 52.5%

liquid paraffin to 100gm„.

The white soft paraffin and liquid paraffin were melted and mixed together to form a homogenous fluid. This fluid was sterilised by passing through a 0.22 micron cellulose ester bacterial filter and collected in a sterile mixing vessel.

The micronised anhydrous salt oftolmetin was sterilised by irradiation by gamma-rays at 2.5 Mrads. This sterile powder was intimately mixed with the white soft paraffin/liquid paraffin mixture aseptic conditions to give a sterile ophthalmically acceptable ointment containing the sodium salt oftolmetin.

Example 12

Sodium salt oftolmetinlchloramphenicol ointment formulation,

Tolmetin sodium anhydrous

(micronised) 1.77%

Chloramphenicol (micronised) 1.0%

White soft paraffin 52.5%

Liquid paraffin to 100g.

The ointment was prepared by the method 100 described in Example 11, the micronised chloramphenicol being sterilised and added in a similar manner to the sodium salt oftolmetin.

55 This solution was then sterilised and packaged in the manner of Example 4.

Example 10

Sodium salt of tolmetin formulation

Aformulation was prepared containing:

60

Tolmetin sodium dihydrate 5.0g

T risodium citrate 1 -0g

Phenylmercuric nitrate 0.002g

Citric acid solution to adjust the pH to 7.5 65 Distilled waterto adjustthe volume to 100 ml.

7

GB 2 075 341 A

7

10

Examples 13 and 14 Sodium salt oftolmetin formulations. Formulations were prepared containing:

Tolmetin sodium dihydrate

Trisodium citrate

Phenylethanol

Thiomersal

Citric acid, 5% solution

Distilled water

A solution was prepared by dissolving 15 phenylethanol and thiomersal in distilled water (25ml). The trisodium citrate was then added and the solution stirred until all the solid had dissolved. The sodium salt of tolmetin was then dissolved in this solution. The pH value of the solution was adjusted 20 to 7.5 by the addition of 5% citric acid solution. The

25

30

35

Examples 15 and 16 Sodium salt of tolmetin formulations Formulations were prepared containing:

Tolmetin sodium dihydrate Trisodium citrate Citric acid 5% solution.

Distilled water

13

2.0% w/v 1.0% w/v 0.5% w/v 0.01 % w/v adjust pHto 7.5 to 100ml.

14

5.0% w/v 1.0% w/v 0.5% w/v 0.01% w/v adjustto pHto 7.5 to 100ml.

volume of the solution was finally raised to 100ml by addition of distilled water.

This solution was sterilised by filtration through a 0.22 micron cellulose ester bacterial filter and asepti-cally filled into multidose sterile glass eye-dropper bottles.

15

2.0% w/v 1.0% w/v adjust pH to 7.5 to 100 ml

16

5.0% w/v 1.0% w/v adjustto 7.5 to 100 ml.

Solutions were prepared by dissolving the sodium citrate and sodium salt oftolmetin in distilled water 40 (25ml), adjusting the pH value to 7.5 with a 5% solution of citric acid and finally adjusting the volume to

100ml with distilled water.

These solutions were then filled in to unit dose packs and sterilised by autoclaving at 116°C for 30 45 minutes.

Examples 17 and 18

Sodium salt of tolmetin—chloroamphenicol formulation.

50 Formulations were prepared containing:

17

18

Tolmetin sodium dihydrate

2.0%

w/v

4.0% w/v

Chloramphenicol

0.5%

w/v

0.5% w/v

Trisodium citrate

1.0%

w/v

1.0% w/v

* Polyvinyl pyrrolidone

10.0%

w/v

10.0% w/v

(number average molecular wt.

40,000)

Thiomersal

0.01%

w/v

0.01% w/v

60 Sodium hydroxide, 5% solution to adjust pH to 7.5 to adjust pH to 7.5

Distilled water to 100 ml to 100 ml

* The polyvinyl pyrrolidone used was Plasdone C-30.

65 To prepare the solutions, the polyvinyl pyrrolidone, sodium citrate, thiomersal and chloramphenicol were added to distilled water (60ml) and stirred until all the solid had dissolved. The sodium salt oftolmetin was then added and the solution stir-70 red until the solid had dissolved. The pH value of the solution was adjusted to 7.5 by addition of 5% sodium hydroxide solution. The volume of the solution was raised to 100ml by addition of distilled water.

75 These solutions were sterilised by filtration through a 0.22 micron cellulose ester bacterial filter and aseptically filled into multidose sterile glass eye-dropper bottles.

8

GB 2 075 341 A

8

10

Examples 19 and 20

Sodium salt of tolmetin—chloramphenicol formulations.

Formulations were prepared containing:

Tolmetin sodium dihydrate Chloramphenicol Trisodium citrate Polyvinyl pyrrolidone Sodium hydroxide, 5% solution Distilled water

19

2.0% w/v 0.5% w/v 1.0% w/v 10.0% w/v to adjust pH to 7.5 to 100ml

20

4.0% w/v 0.5% w/v 1.0% w/v 10.0% w/v to adjust pH to 7.5 to 100ml.

15 The solutions were prepared as described for Examples 17 and 18.

The solutions were filled into unit-dose packs and sterilised by autoclaving at 100°Cfor30 minutes. Example 21,22 and 23 20 Sodium salt of tolmetin water-in-oil emulsion.

Formulations of the sodium salt oftolmetin in the form of an emulsion (water-in-oil type) were prepared as follows:

25

30

35

21

22

23

Tolmetin sodium dihydrate

2.0%

Trisodium citrate

0.1%

Phenylethanol

0.5%

* Glyceryl monoisostearate

5.0%

3.0%

Water

34.9%

Cetostearyl alcohol

12.5%

—

Liquid paraffin

22.5%

27.5%

26.5%

White soft paraffin

22.5%

20.0%

hydrogenated castor oil

—

10.0%

Sorbitan sesquioleate

—

3.0%

lmwitor780K, registered trade mark of Dynamit Nobel.

The emulsions were prepared as follows. The sodium salt oftolmetin and trisodium citrate were 40 dissolved in the water and the resultant solution heated to 75-80°C. The remaining components, constituting the oil phase, were mixed together and heated to 80°C with stirring to produce a homogenous oily liquid. Whilst maintaining the temperature 45 and stirring the aqueous solution was added to the oily liquid and the emulsion so formed allowed to cool with stirring. The product was produced as a stable emulsion of the water-in-oil type.

Claims

50 1. An anti-inflammatory pharmaceutical composition containing as active principle a compound of formula,

55

60

CHR2 COOH

or a pharmaceutical^ acceptable salt thereof wherein R, is a chlorine atom or a methyl group, R2 is a hydrogen atom or a methyl group and R3 is hyd-65 rogen atom or a methyl group which is adapted for topical application to the eye.

2. A composition as claimed in claim 1 which contains from 0.1 to 10.0% of the active principle.

3. A composition as claimed in either of claims 1 70 or 2 which contains from 0.4 to 7.0% of the active principle.

4. A composition as claimed in any of claims 1 to 3 which contains from 0.5 to 5% of the active principle.

75 5. A composition as claimed in any of claims 1 to 4which contains from 1 to2%or2to 5%ofthe active principle. .

6. A composition as claimed in any of claims 1 to

5 in which the active principle is the sodium or 80 potassium salt oftolmetin.

7. A composition *s claimed in any of claims 1 to

6 in which the active principle is the sodium salt of tolmetin.

8. A compositionsas claimed in any of claims 1 to 85 5 tn which the active prirtciple is the sodium salt of tolmetin in the form of its dihydrate.

9. A composition asclaimed in any of claims 1 to 5 or 8 in which the active principle is the sodium salt of tolmetin in the form of its anhydrate.

90 10. A composition as claimed in any of claims 1 to 9 in which the composition is in the form of a clear, sterile, substantially isotonic, aqueous solution.

9

GB 2 075 341 A

9

11. A composition as claimed in claim 10 which contains a sequestering agent.

12. Acompositions as claimed in claim 11 in which the sequestering agent is a salt of citric acid,

5 ethylene diamine tetracetic acid or salt thereof or 8-hydroxyquinoline.

13. Acomposition as claimed in claim 12 in

- which the sequestering agent is trisodium citrate.

14. Acomposition as claimed in any of claims 10

10 to 12 which contains from 0.001 to 2% of sequester-

» ing agent.

15. Acomposition as claimed in any of claims 1 to 14 which contains an antioxidant.

16. Acomposition as claimed in claim 15 in

15 which the antioxidant is a salt of citric acid, a thiosulphate salt, a bisulphite salt orthiourea.

17. Acomposition as claimed in claim 16 in which the antioxidant is trisodium citrate.

18. Acompositions as claimed in any of claims

20 15 to 17 which contains from 0.01 to 2.5% of antioxidant.

19. Acomposition as claimed in any of claims 1 to 18 which contains a preservative.

20. Acomposition as claimed in claim 19 in

25 which the preservative is chlorocresol, thiomersal, phenylethanol or mixtures thereof.

21. A compositions as claimed in any of claims 19 or 20 in which the preservative is phenylethanol together with thiomersal.

30 22. Acomposition as claimed in claim 21 which contains from 0.1 to 1% of phenylethanol together with 0.001 to 0.025% thiomersal.

23. Acomposition as claimed in claim 22 which contains 0.5% phenylethanol together with 0.01%

35 thiomersal.

24. Acomposition as claimed in any of claims 1 to 23 which contains an aminoglycoside or a phar-maceutically acceptable salt thereof.

25. Acomposition as claimed in claim 24 in

40 which the aminoglycoside is neomycin, gentamycin, framycetin, polymixin B, tobramycin, kanamycin, vanomycin, amikocin or salts thereof.

26. A composition as claimed in claim 25 in which the aminoglycoside is neomycin sulphate.

45 27. Acomposition as claimed in any of claims 24 to 26 which contains from 0.5 to 5% of aminoglycoside.

28. A composition as claimed in any of claims 1

„ to 23 which contains chloroamphenicol.

50 29. Acomposition as claimed in claim 28 which contains from 0.1 to 3.0% of chloramphenicol.

30. Acomposition as claimed in any of claims 24 to 28 which contains a solubilising agent.

31. A composition as claimed in claim 30 in

55 which the solubilising agent is polyvinyl pyrrolidone, polyvinyl alcohol or mixtures thereof.

32. A composition as claimed in claim 31 in which the solubilising agent is polyvinyl pyrrolidone.

33. Acomposition as claimed in any of claims 30

60 to 32 in which the composition contains from 1 to

20% of the solubilising agent.

34. A composition as claimed in any of claims 10 to 33 in which the pH of the composition is from 6 to 8.5.

65 35. Acomposition as claimed in any of claims 10

to 34 in which the pH is from 7 to 8.

36. A composition as claimed in any of claims 1 to 9 in which the composition is in the form of a sterile ointment.

70 37. A composition as claimed in claim 36 which contains an aminoglycoside.

38. A composition as claimed in claim 37 in which the composition contains from 0.5 to 5% of the aminoglycoside.

75 39. Acomposition as claimed in either claim 37 or 38 in which the aminoglycoside is neomycin sulphate.

40. A composition as claimed in claim 36 which contains chloroamphenicol.

80 41. A composition as claimed in claim 40 which contains 0.1 to 3.0% chloramphenicol.

42. Acomposition as claimed in any ofclaims36 to 41 which contains liquid paraffin together with white soft paraffin.

85 43. Acomposition as claimed in claim 42 in which the ratio of white soft paraffin to liquid paraffin is 0.8:1 to 1:1.

44. Acomposition as claimed in any of claims 1 to 9 in which the composition is in the form of a

90 sterile emulsion.

45. A composition as claimed in claim 44 which contains emulsifying agent.

46. A composition as claimed in claim 45 in which the emulsifying agent is glyceryl monoisos-

95 tearate, cetostearyl alcohol, hydrogenated castor oil or sorbitan sesquioleate or mixtures thereof.

47. A composition as claimed in either claim 44 or 45 which contains from 1 to 20% of emulsifying agent.

100 48. Acomposition as claimed in any one of claims 44 to 47 which contains preservative.

49. Acomposition as claimed in claim 48 in which the preservative is chlorbutanol, chlorocresol, benzalkonium chloride, thiomersal, phenylethanol,

105 phenoxyethanol or mixtures thereof.

50. A composition as claimed in claim 49 in which the preservative is phenylethanol.

51. A composition as claimed in claim 50 which contains from 0.1 to 1% of phenylethanol.

110 52. Acomposition as claimed in any of claims 44 to 51 which contains an antioxidant.

53. Acomposition as claimed in claim 52 in which the antioxidant is trisodium citrate.

54. A composition as claimed in claim 53 which

115 contains 0.1 to 2% of trisodium citrate.

55. A composition as claimed in any of claims 44 to 54 in which the oil comprises vegetable oils, mineral oils, castor oil, liquid paraffin, white soft paraffin or mixtures thereof.

120 56. Acomposition as claimed in claim 55 which contains from 40 to 65% of oil.

Printed for Her Majesty's Stationery Office by The Tweeddale Press Ltd., Berwick-upon-Tweed, 1981.

Published at the Patent Office, 25 Southampton Buildings, London, WC2A1 AY, from which copies may be obtained.